Avicenna Holdings Limited has been acquired by Juno Health
The shareholders of Avicenna Holdings Limited have sold the business to Juno Health.
Based in the UK, Avicenna comprises 21 pharmacies, as well as a buying group operation serving more than 1,000 independent pharmacies.
Juno Health is a UK-based company that operates a chain of pharmacy stores. The community pharmacies will be integrated into Juno’s existing chain with the buying group continuing to be run by Salim Jetha, Avicenna CEO. It will become the industry-leading buying and support group for independent pharmacies across the UK. Juno has considerable experience in the sector and the combination of Avicenna resources and expertise will support the independent pharmacy sector and improve membership benefits.
Richard Smith, Chairman at Juno Health, said: “Avicenna is a well-established business delivering clear benefits to its members. It is one of the most recognizable brands among independent pharmacists and extremely well respected.”
Oaklins Cavendish, based in the UK, advised the shareholders of Avicenna on the sale of the business to Juno Health.
Talk to the deal team
Related deals
Vivo Diagnóstico has been acquired by NEXXUS-IBERIA SGEIC, S.A.
NEXXUS-IBERIA SGEIC, S.A. a private equity firm in Spain, has completed its acquisition of a majority stake in Vivo Diagnóstico. With this financial backing from NEXXUS-IBERIA, Vivo will focus on inorganic growth as well as investing in service quality, innovation and efficiency.
Learn moreGroupe JVS has completed an LBO with Capza and Bpifrance
The shareholders of Groupe JVS have completed an LBO with Capza and BpiFrance. Parquest sold their shares after partnering with the organization for three years. Groupe JVS’s management team will increase its ownership and remain as the majority shareholder of the group, alongside CAPZA and Bpifrance.
Learn moreCreo Medical Group plc has completed a US$15.7 million equity fundraise
Creo Medical Group plc, the provider of pioneering endoscopic healthcare solutions to clinicians and healthcare providers across the world, has completed a US$15.7 million (£12.1 million) equity fundraise.
Learn more